Scorpius Holdings Inc (Scorpius Holdings) is an immuno-oncology focused biopharmaceutical company specializes in comprehensive end-to-end processes encompassing the development, manufacturing, and commercialization of innovative medical countermeasures. These countermeasures are specifically designed to combat unmet and emerging biothreats, addressing the needs and challenges posed by potential biological hazards.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Scorpius Holdings has established an extensive research and development organization, both internally and externally, encompassing a wide range of expertise. This includes proficiency in discovery research, preclinical development, product formulation, analytical chemistry, manufacturing, clinical development, as well as regulatory and quality assurance. The company incurred research and development expenses amounting to US$23.5 million and US$16.5 million for the years ended December 31, 2022, and 2021, respectively.